Vertex PharmaceuticalsVRTX
About: Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Employees: 5,400
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
28% more call options, than puts
Call options by funds: $938M | Put options by funds: $731M
12% more first-time investments, than exits
New positions opened: 119 | Existing positions closed: 106
8% more repeat investments, than reductions
Existing positions increased: 617 | Existing positions reduced: 573
1% less funds holding
Funds holding: 1,528 [Q2] → 1,520 (-8) [Q3]
3% less capital invested
Capital invested by funds: $114B [Q2] → $111B (-$3.79B) [Q3]
2.52% less ownership
Funds ownership: 94.89% [Q2] → 92.36% (-2.52%) [Q3]
9% less funds holding in top 10
Funds holding in top 10: 32 [Q2] → 29 (-3) [Q3]
Research analyst outlook
17 Wall Street Analysts provided 1 year price targets over the past 3 months
17 analyst ratings
Wells Fargo Mohit Bansal 31% 1-year accuracy 8 / 26 met price target | 9%upside $460 | Overweight Maintained | 10 Jan 2025 |
Truist Securities Joon Lee 49% 1-year accuracy 20 / 41 met price target | 9%upside $460 | Buy Maintained | 23 Dec 2024 |
Scotiabank Greg Harrison 36% 1-year accuracy 10 / 28 met price target | 2%upside $430 | Sector Perform Maintained | 23 Dec 2024 |
JP Morgan Jessica Fye 47% 1-year accuracy 18 / 38 met price target | 18%upside $500 | Overweight Maintained | 23 Dec 2024 |
Barclays Gena Wang 16% 1-year accuracy 5 / 31 met price target | 1%downside $418 | Equal-Weight Maintained | 20 Dec 2024 |
Financial journalist opinion
Based on 44 articles about VRTX published over the past 30 days
